Vivos Therapeutics, Inc.
VVOS
$3.37
$0.3210.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -18.44% | -4.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.44% | -4.20% | |||
| Cost of Revenue | -5.87% | 4.91% | |||
| Gross Profit | -28.04% | -10.15% | |||
| SG&A Expenses | 10.32% | -1.53% | |||
| Depreciation & Amortization | 22.92% | -1.37% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.61% | -0.02% | |||
| Operating Income | -39.63% | -6.09% | |||
| Income Before Tax | -36.68% | -8.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -36.68% | -8.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -36.68% | -8.07% | |||
| EBIT | -39.63% | -6.09% | |||
| EBITDA | -40.53% | -6.52% | |||
| EPS Basic | -14.99% | 36.01% | |||
| Normalized Basic EPS | -15.02% | 36.01% | |||
| EPS Diluted | -14.99% | 36.01% | |||
| Normalized Diluted EPS | -15.02% | 36.01% | |||
| Average Basic Shares Outstanding | 18.84% | 68.91% | |||
| Average Diluted Shares Outstanding | 18.84% | 68.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||